Literature DB >> 20131843

Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.

Alexander Breuning1, Björn Degel, Franziska Schulz, Christian Büchold, Martin Stempka, Uwe Machon, Saskia Heppner, Christoph Gelhaus, Matthias Leippe, Matthias Leyh, Caroline Kisker, Jennifer Rath, August Stich, Jiri Gut, Philip J Rosenthal, Carsten Schmuck, Tanja Schirmeister.   

Abstract

New peptidic Michael acceptor based cysteine protease inhibitors displaying antiparasitic activity were identified by testing a broad series of 45 compounds in total, containing Asn, Gln, or Phe. As target enzymes, falcipain-2 and -3 from P. falciparum and rhodesain from T. b. rhodesiense were used. In the case of the Asn/Gln containing compounds, the trityl-protected, diastereomeric E-configured vinylogous dipeptide esters 16 (Boc-(S)-Phg-(R/S)-vGln(Trt)-OEt) were discovered as most active inhibitors concerning both protease inhibition and antiparasitic acitivity, with inhibition constants in the submicromolar range. The compounds were shown to display time-dependent and competitive inhibition. In the case of the Phe containing compounds, the maleic acid derivatives 42 and 43 (BnO-Phe<--Mal-Phe-OBn, BnO-Phe<--Mal-Phe-Ala-OBn, Mal = maleic acid) displayed good inhibition of rhodesain as well as good antitrypanosomal activity, while the fumaric acid derived E-analogue 14 (BnO-Phe<--Fum-Phe-OBn) only displayed inhibition of the target enzymes but no antiparasitic activity. Inhibition by these Phe derivatives was shown to be time-independent and competitive.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20131843     DOI: 10.1021/jm900946n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

Review 1.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

2.  Anti-trypanosomal activities and structural chemical properties of selected compound classes.

Authors:  Alicia Ponte-Sucre; Heike Bruhn; Tanja Schirmeister; Alexander Cecil; Christian R Albert; Christian Buechold; Maximilian Tischer; Susanne Schlesinger; Tim Goebel; Antje Fuß; Daniela Mathein; Benjamin Merget; Christoph A Sotriffer; August Stich; Georg Krohne; Markus Engstler; Gerhard Bringmann; Ulrike Holzgrabe
Journal:  Parasitol Res       Date:  2014-11-23       Impact factor: 2.289

3.  Development of Urea-Bond-Containing Michael Acceptors as Antitrypanosomal Agents Targeting Rhodesain.

Authors:  Santo Previti; Roberta Ettari; Elsa Calcaterra; Carla Di Chio; Rahul Ravichandran; Collin Zimmer; Stefan Hammerschmidt; Annika Wagner; Marta Bogacz; Sandro Cosconati; Tanja Schirmeister; Maria Zappalà
Journal:  ACS Med Chem Lett       Date:  2022-06-30       Impact factor: 4.632

4.  Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases.

Authors:  Caroline Schad; Ulrike Baum; Benjamin Frank; Uwe Dietzel; Felix Mattern; Carlos Gomes; Alicia Ponte-Sucre; Heidrun Moll; Uta Schurigt; Tanja Schirmeister
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

5.  New tetromycin derivatives with anti-trypanosomal and protease inhibitory activities.

Authors:  Sheila M Pimentel-Elardo; Verena Buback; Tobias A M Gulder; Tim S Bugni; Jason Reppart; Gerhard Bringmann; Chris M Ireland; Tanja Schirmeister; Ute Hentschel
Journal:  Mar Drugs       Date:  2011-09-26       Impact factor: 6.085

6.  Identification of the protease inhibitor miraziridine A in the Red sea sponge Theonella swinhoei.

Authors:  Paula Tabares; Björn Degel; Norbert Schaschke; Ute Hentschel; Tanja Schirmeister
Journal:  Pharmacognosy Res       Date:  2012-01

7.  Identification of plakortide E from the Caribbean sponge Plakortis halichondroides as a trypanocidal protease inhibitor using bioactivity-guided fractionation.

Authors:  Swarna Oli; Usama Ramadan Abdelmohsen; Ute Hentschel; Tanja Schirmeister
Journal:  Mar Drugs       Date:  2014-05-02       Impact factor: 5.118

8.  Naphthoquinones as Covalent Reversible Inhibitors of Cysteine Proteases-Studies on Inhibition Mechanism and Kinetics.

Authors:  Philipp Klein; Fabian Barthels; Patrick Johe; Annika Wagner; Stefan Tenzer; Ute Distler; Thien Anh Le; Paul Schmid; Volker Engel; Bernd Engels; Ute A Hellmich; Till Opatz; Tanja Schirmeister
Journal:  Molecules       Date:  2020-04-28       Impact factor: 4.411

9.  Antioxidant and anti-protease activities of diazepinomicin from the sponge-associated Micromonospora strain RV115.

Authors:  Usama Ramadan Abdelmohsen; Matthias Szesny; Eman Maher Othman; Tanja Schirmeister; Stephanie Grond; Helga Stopper; Ute Hentschel
Journal:  Mar Drugs       Date:  2012-10-08       Impact factor: 6.085

10.  Screening a Natural Product-Based Library against Kinetoplastid Parasites.

Authors:  Bilal Zulfiqar; Amy J Jones; Melissa L Sykes; Todd B Shelper; Rohan A Davis; Vicky M Avery
Journal:  Molecules       Date:  2017-10-12       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.